AU2021223191A1 - Compositions and therapeutic uses of cannabidiol - Google Patents

Compositions and therapeutic uses of cannabidiol Download PDF

Info

Publication number
AU2021223191A1
AU2021223191A1 AU2021223191A AU2021223191A AU2021223191A1 AU 2021223191 A1 AU2021223191 A1 AU 2021223191A1 AU 2021223191 A AU2021223191 A AU 2021223191A AU 2021223191 A AU2021223191 A AU 2021223191A AU 2021223191 A1 AU2021223191 A1 AU 2021223191A1
Authority
AU
Australia
Prior art keywords
cannabidiol
syndrome
navi
pharmaceutical composition
gating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021223191A
Other languages
English (en)
Inventor
Koushik CHOUDHURY
Mohamed Amin FOUDA
Mohammad-Reza GHOVANLOO
Vishal Anant Jadhav
Dana A. Page
Manit PATEL
Tejas PHATERPEKAR
Rusinova RADDA
Peter Charles RUBEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merchant Shreema
Original Assignee
Merchant Shreema
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merchant Shreema filed Critical Merchant Shreema
Publication of AU2021223191A1 publication Critical patent/AU2021223191A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021223191A 2020-02-19 2021-02-19 Compositions and therapeutic uses of cannabidiol Pending AU2021223191A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202021007184 2020-02-19
IN202021007184 2020-02-19
IN202021013770 2020-03-29
IN202021013770 2020-03-29
PCT/IN2021/050159 WO2021165992A1 (en) 2020-02-19 2021-02-19 Compositions and therapeutic uses of cannabidiol

Publications (1)

Publication Number Publication Date
AU2021223191A1 true AU2021223191A1 (en) 2022-10-13

Family

ID=77391770

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021223191A Pending AU2021223191A1 (en) 2020-02-19 2021-02-19 Compositions and therapeutic uses of cannabidiol

Country Status (9)

Country Link
US (1) US20230123654A1 (https=)
EP (1) EP4106870A4 (https=)
JP (1) JP2023516284A (https=)
CN (1) CN115916336A (https=)
AU (1) AU2021223191A1 (https=)
CA (1) CA3171890A1 (https=)
IL (1) IL295753A (https=)
WO (1) WO2021165992A1 (https=)
ZA (1) ZA202210355B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296892A (en) * 2020-03-29 2022-12-01 Akseera Pharma Corp Interaction of sars-cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of covid -19
AU2021250462A1 (en) * 2020-04-02 2022-12-01 Incannex Healthcare Limited Methods and compositions for treating or preventing an inflammatory condition
WO2022122904A1 (en) * 2020-12-09 2022-06-16 Chanelle Mccoy Cbd Limited A delayed-release capsule of cannabidiol
AU2022204290A1 (en) * 2020-12-12 2023-07-27 Akseera Pharma Corp. Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19
IL309886A (en) * 2021-07-15 2024-03-01 Incannex Healthcare Ltd A preparation containing cannabidiol and hydroxychloroquine in a combined capsule at a fixed dose
JPWO2024043242A1 (https=) * 2022-08-23 2024-02-29

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087374B2 (en) * 2003-06-26 2006-08-08 The Research Foundation Of State University Of New York Screen for sodium channel modulators
MX376077B (es) * 2013-03-13 2025-03-07 Univ Cincinnati Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
WO2016161138A1 (en) * 2015-03-31 2016-10-06 Stamets Paul Edward Antiviral activity from medicinal mushrooms and their active constituents
LT6486B (lt) * 2016-04-13 2018-01-10 UAB "SatiMed" Aliejinio gelio kompozicija su aktyviausiais junginiais iš c. sativa ir m. arvensis ir jos pateikimo sistema, skirta giliųjų audinių uždegimo ir skausmo mažinimui
IL262713B2 (en) * 2016-05-02 2024-07-01 Stero Biotechs Ltd Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases
CN108079305A (zh) * 2016-11-23 2018-05-29 汉义生物科技（北京）有限公司 大麻二酚与三环类抗抑郁药的药物组合物及其用途
AU2018273410A1 (en) * 2017-05-26 2020-01-16 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
US20210085801A1 (en) * 2017-12-12 2021-03-25 Cardiol Therapeutics Inc. Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure
KR102632946B1 (ko) * 2018-01-13 2024-02-05 트루티바 인코포레이티드 노화 방지 및 피부 톤 미백 조성물 및 이를 위한 방법
CN110575448A (zh) * 2018-06-08 2019-12-17 云南汉素生物科技有限公司 大麻二酚组合物及其用途
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients

Also Published As

Publication number Publication date
CN115916336A (zh) 2023-04-04
IL295753A (en) 2022-10-01
JP2023516284A (ja) 2023-04-19
US20230123654A1 (en) 2023-04-20
WO2021165992A1 (en) 2021-08-26
EP4106870A4 (en) 2024-04-10
EP4106870A1 (en) 2022-12-28
CA3171890A1 (en) 2021-08-26
ZA202210355B (en) 2024-02-28

Similar Documents

Publication Publication Date Title
US20230123654A1 (en) Compositions and therapeutic uses of cannabidiol
EP2560624B1 (en) Therapeutic formulation for reduced drug side effects
US8753674B2 (en) Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US8802702B2 (en) Compounds for reducing drug resistance and uses thereof
US20090192220A1 (en) Treatment for solid tumors
US12514819B2 (en) Colchicine drug-to-drug interactions
ES2773834T3 (es) Métodos y composiciones para tratar la depresión usando ciclobenzaprina
CN106029070A (zh) 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途
US20240197817A1 (en) Compositions for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions, and uses thereof
US11071731B2 (en) Allosteric modulators of the mu opioid receptor
WO2019094434A1 (en) Therapeutic combination for treatment of cerebellar ataxia
US11234964B2 (en) Use of melatonin for the treatment of tumors
WO2025031474A1 (en) Method and medicament for treating endometriosis
HK40077420A (zh) 一种抗抑郁和抗焦虑的取代桂皮酰胺化合物
WO2022247834A1 (zh) 一种抗抑郁和抗焦虑的取代桂皮酰胺化合物
CN117597113A (zh) 用于治疗自身免疫、同种免疫、炎性和线粒体疾患的组合物及其用途
WO2020257753A1 (en) Phosphatidylserine decarboxylase inhibitors
HK40023902A (en) Use of melatonin for the treatment of tumours